Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury ; volume:17 ; number:1 ; day:30 ; month:7 ; year:2018 ; pages:1-14 ; date:12.2018
Cardiovascular diabetology ; 17, Heft 1 (30.7.2018), 1-14, 12.2018
- Classification
-
Medizin, Gesundheit
- Creator
-
Aroor, Annayya R.
- Contributor
-
Das, Nitin A.
Carpenter, Andrea J.
Habibi, Javad
Jia, Guanghong
Ramirez-Perez, Francisco I.
Martinez-Lemus, Luis
Manrique-Acevedo, Camila M.
Hayden, Melvin R.
Duta, Cornel
Nistala, Ravi
Mayoux, Eric
Padilla, Jaume
Chandrasekar, Bysani
DeMarco, Vincent G.
SpringerLink (Online service)
- DOI
-
10.1186/s12933-018-0750-8
- URN
-
urn:nbn:de:101:1-2018100121373564301197
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aroor, Annayya R.
- Das, Nitin A.
- Carpenter, Andrea J.
- Habibi, Javad
- Jia, Guanghong
- Ramirez-Perez, Francisco I.
- Martinez-Lemus, Luis
- Manrique-Acevedo, Camila M.
- Hayden, Melvin R.
- Duta, Cornel
- Nistala, Ravi
- Mayoux, Eric
- Padilla, Jaume
- Chandrasekar, Bysani
- DeMarco, Vincent G.
- SpringerLink (Online service)
Other Objects (12)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Die Glukosesenkung mit dem SGLT2-Hemmer Empagliflozin verbessert die Atheroskleroseregression in der hyperglykämischen STZ-diabetischen Maus
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Die Glukosesenkung mit dem SGLT2-Hemmer Empagliflozin verbessert die Atheroskleroseregression in der hyperglykämischen STZ-diabetischen Maus
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice